Muneeb Ullah | Nanobiotechnology | Best Paper Award

Published on by Nano Technology

Mr. Muneeb Ullah | Nanobiotechnology | Best Paper Award

PhD Student | Pusan National University | South Korea

Mr. Muneeb Ullah is an accomplished nanomedicine researcher specializing in pharmaceutical nanotechnology, drug delivery systems, and biomaterials for therapeutic applications. His research primarily focuses on the synthesis and characterization of nanoparticles for wound healing, colorectal cancer, diabetic wound treatment, and inflammatory bowel diseases. He has published 38 scientific documents with 504 citations and an h-index of 11, reflecting strong and consistent contributions to high-impact biomedical research. Mr. Muneeb Ullah has authored numerous peer-reviewed journal papers and book chapters in leading outlets such as Chemical Engineering Journal, Small, Carbohydrate Polymer Technologies & Applications, European Polymer Journal, Journal of Pharmaceutical Investigation, and Current Problems in Cardiology. His works have collectively accumulated an impressive total impact factor exceeding 120. His notable contributions include advancements in nanoparticle-based therapeutics, 3D and 4D bioprinting, nanocarbon-based biomedical materials, and smart wound-healing systems. He has also co-authored multiple academic books and chapters published by CRC Press and Academic Press, covering topics such as fungal biotechnology, gastrointestinal inflammation, carbon dots, cancer nanomedicine, and nanotechnology in wound healing. His interdisciplinary collaborations have led to innovations in biofilm-associated therapies, tissue engineering, and targeted drug delivery systems. Recognized as a Best Researcher Award recipient in 2024 and 2025, Mr. Muneeb Ullah’s scholarly impact extends to editorial and reviewer services for international journals. His ongoing projects explore novel nanocluster adhesives, biopolymer-based nanostructures, and tumor-selective delivery mechanisms. Through his pioneering R&D initiatives, Mr. Muneeb Ullah continues to advance the frontiers of nanomedicine, combining pharmaceutical technology with molecular innovation to address complex biomedical challenges globally.

Profiles: Scopus | ResearchGate | Sci Profiles | Scholar GPS

Featured Publications

1. Safdar, M., Ullah, M., Hamayun, S., Wahab, A., Khan, S. U., Abdikakhorovich, S. A., Haq, Z. U., Mehreen, A., Naeem, M., Mustopa, A. Z., & Hasan, N. (2024). Microbiome miracles and their pioneering advances and future frontiers in cardiovascular disease. Current Problems in Cardiology, 49(9), 102686. https://doi.org/10.1016/j.cpcardiol.2024.102686

2. Khan, M. A., Khan, N., Ullah, M., Hamayun, S., Makhmudov, N. I., Mbbs, R., Safdar, M., Bibi, A., Wahab, A., Naeem, M., & Hasan, N. (2024). 3D printing technology and its revolutionary role in stent implementation in cardiovascular disease. Current Problems in Cardiology, 49(6), 102568. https://doi.org/10.1016/j.cpcardiol.2024.102568

3. Khan, S. U., Ullah, M., Saeed, S., Saleh, E. A. M., Kassem, A. F., Arbi, F. M., Wahab, A., Rehman, M., ur Rehman, K., Khan, D., … & Lu, K. (2024). Nanotherapeutic approaches for transdermal drug delivery systems and their biomedical applications. European Polymer Journal, 207, 112819. https://doi.org/10.1016/j.eurpolymj.2024.112819

4. Khan, S. U., Huang, Y., Ali, H., Ali, I., Ahmad, S., Khan, S. U., Hussain, T., Ullah, M., & Lu, K. (2024). Single-cell RNA sequencing (scRNA-seq): Advances and challenges for cardiovascular diseases (CVDs). Current Problems in Cardiology, 49(2), 102202. https://doi.org/10.1016/j.cpcardiol.2023.102202

5. Zeb, F., Mehreen, A., Naqeeb, H., Ullah, M., Waleed, A., Awan, U. A., Haider, A., & Naeem, M. (2024). Nutrition and dietary intervention in cancer: Gaps, challenges, and future perspectives. In Nutrition and Dietary Interventions in Cancer (pp. 281–307). Springer Nature Switzerland. https://doi.org/10.1007/978-3-031-55622-7_11

David Stejskal | Nanobiotechnology | Best Researcher Award

Published on by Nano Technology

Prof. Dr. David Stejskal | Nanobiotechnology | Best Researcher Award

Professor, MD, PhD, MBA, EuSpLM, Head of the Institute of Laboratory Medicine | University Hospital in Ostrava | Czech Republic

Prof. Dr. David Stejskal, MD, PhD, MBA, EuSpLM, is a distinguished researcher and academic leader in the field of laboratory medicine, clinical biochemistry, and internal medicine. His research primarily focuses on the identification and clinical validation of novel biomarkers relevant to metabolic, cardiovascular, nephrological, and inflammatory diseases. With over 3,767 citations, an h-index of 29 (Scopus), and more than 200 peer-reviewed publications, his scholarly influence spans translational diagnostics and clinical applications in metabolic and endocrine disorders. His most cited works include pioneering studies on fatty acid binding proteins (FABP), chemerin, and FGF23, which have significantly advanced understanding of biomarkers in metabolic syndrome, chronic kidney disease, and cardiovascular risk assessment. Prof. Dr. David Stejskal’s research group has also contributed substantially to the development of novel diagnostic markers for diabetes, obesity, and atherosclerosis, as well as the evaluation of inflammatory and oxidative stress parameters in internal medicine. Beyond journal publications, he has authored and co-authored several scientific books such as Metabolic Diseases of Mass Incidence, Dyslipidemia, and Urolithiasis, alongside chapters in specialized medical encyclopedias. His work has been instrumental in shaping biomarker-based diagnostic strategies across Central Europe. Prof. Dr. David Stejskal has received notable research and organizational recognitions, including the OMICS Award (USA) for excellence in translational medicine and the Czech Society of Clinical Biochemistry Award. As an editorial contributor, reviewer, and conference organizer, he has significantly influenced international collaboration in laboratory and clinical research. His continued focus on biochemical innovation, diagnostic optimization, and translational research highlights his contribution to advancing laboratory medicine and evidence-based clinical diagnostics globally.

Profiles: Scopus | ORCID | ResearchGate | Sci Profiles | Web of Science

Featured Publications

1. Sigutova, R., Evin, L., Kusnierova, P., Svagera, Z., Branny, M., & Vaclavik, J. (2025). Specific microRNAs for heart failure: Reference values in whole blood. Biomedicines, 13(10), 2559. https://doi.org/10.3390/biomedicines13102559

2. Urinovska, R., Sistik, P., Buzga, M., & Stejskal, D. (2024). Fast and easy simultaneous determination of riboflavin, folic acid, all-trans-retinol and α-tocopherol in human serum by LC/MS/MS for bariatric patients. Journal of Chromatographic Science. https://doi.org/10.1093/chromsci/bmae035

3. Johannsen, B., Baumgartner, D., Karpíšek, M., Paust, N., Zengerle, R., & Mitsakakis, K. (2024). Integration of a bead-based immunoassay on a commercial PCR-performing POC device. Proceedings, 2024(097166). https://doi.org/10.3390/proceedings2024097166

4. Johannsen, B., Baumgartner, D., Karpíšek, M., Paust, N., Zengerle, R., & Mitsakakis, K. (2023). Patient stratification for antibiotic prescriptions based on the bound-free phase detection immunoassay of C-reactive protein in serum samples. Biosensors, 13(12), 1009. https://doi.org/10.3390/bios13121009

5. Plášek, J., Lazárová, M., Dodulík, J., Švagera, Z., Všianský, F., & Václavík, J. (2022). Secretoneurin as a novel biomarker of cardiovascular episodes: Are we there yet? A narrative review. Journal of Clinical Medicine, 11(23), 7191. https://doi.org/10.3390/jcm11237191

Sunny Kumar | Nanobiotechnology | Young Scientist Award

Published on by Nano Technology

Mr. Sunny Kumar | Nanobiotechnology | Young Scientist Award

Researcher, CSIR-Indian Institute Of Chemical Biology, India

Mr. Sunny Kumar is an emerging researcher in cancer biology and nanomedicine, recognized for his interdisciplinary contributions that bridge molecular oncology, tumor microenvironment studies, and nanotechnology-driven therapeutics. With an h-index of 6, 11 publications, and 148 citations (as indexed in Scopus), his research reflects both productivity and impact within translational cancer science. His primary research focuses on elucidating the molecular mechanisms underlying glioma, colorectal, and breast cancer progression, emphasizing protein quality control systems such as the ubiquitin-proteasome system and their regulatory influence on oncogenic signaling. Mr. Sunny Kumar has explored novel therapeutic targets like E3 ligases (CHIP), PD-1/PD-L1 pathways, and HAUSP-MDM2 axes, offering valuable insights for cancer immunotherapy and personalized treatment strategies. In addition to mechanistic studies, Mr. Sunny Kumar integrates nanobiotechnology and drug delivery innovation, developing nanoparticle-based formulations capable of crossing the blood–brain barrier for targeted glioma therapy. His research on dual-drug nanotherapeutics and carbon nanotube-based diagnostic platforms has contributed to the advancement of precision medicine approaches for difficult-to-treat cancers. He has published extensively as first or corresponding author in high-impact journals such as Genes & Diseases (IF 9.4), BBA-Molecular Cell Research (IF 3.7), International Journal of Pharmaceutics (IF 5.2), and Journal of Medicinal Chemistry (IF 6.8). His scholarly output also includes multiple book chapters with Springer and Taylor & Francis, covering cancer proteomics, personalized therapy, and nanotherapeutics. Mr. Sunny Kumar serves as a peer reviewer for reputed journals, including BBA–Reviews on Cancer and Experimental Cell Research, further demonstrating his engagement in the scientific community. His research exhibits a robust methodological framework, integrating cell and molecular biology, bioinformatics, animal models, and nanocarrier engineering. Collectively, Mr. Sunny Kumar’s scientific endeavors underscore a commitment to next-generation cancer therapeutics, aiming to translate molecular discoveries into clinically viable nanomedicine solutions for precision oncology.

Profile: Scopus | ORCID | Google Scholar | RsearchGate

Featured Publications

1. Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2023). Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes & Diseases, 10(4), 1318–1350.

2. Kumar, S., Basu, M., & Ghosh, M. K. (2022). Chaperone-assisted E3 ligase CHIP: A double agent in cancer. Genes & Diseases, 9(6), 1521–1555.

3. Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2023). COVID‐19: Clinical status of vaccine development to date. British Journal of Clinical Pharmacology, 89(1), 114–149.

4. Kumar, S., Basu, M., Ghosh, P., Pal, U., & Ghosh, M. K. (2023). COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. Genes & Diseases, 10(4), 1402–1428.

5. Ghosh, M. K., Kumar, S., Ganguly, K. K., Ghosh, P., Tabassum, S., Basu, B., & Basu, M. (2023). COVID-19 and cancer: Insights into their association and influence on genetic and epigenetic landscape. Epigenomics, 15(4), 227–248.

 

Mr. José Robério de Oliveira Netto | Nanobiotechnology | Best Researcher Award

Published on by Nano Technology

Mr. José Robério de Oliveira Netto | Nanobiotechnology | Best Researcher Award

Mr. José Robério de Oliveira Netto at Universidade Potiguar – UnP, Brazil

José Robério de Oliveira Netto is a Brazilian biotechnologist and doctoral candidate at the Federal University of Rio Grande do Norte (UFRN) through the Northeast Biotechnology Network (RENORBIO). He holds a bachelor’s degree from Universidade Potiguar (2014–2018) and a postgraduate specialization in Clinical and Toxicological Analyses from UFRN (2019–2021). His research focuses on the biotechnological decontamination of water and the development of nanoformulations for drug delivery. José Robério has contributed to several notable scientific works, including publications on the bioavailability of natural compounds like trans-dehydrocrotonin and the applications of copaiba oil in pharmacology and nanotechnology. His academic and professional journey reflects a strong commitment to advancing health-focused biotechnological solutions through innovative research.

Professional Profile:

ORCID

Summary of Suitability for Best Researcher Award: Mr. José Robério de Oliveira Netto

Mr. José Robério de Oliveira Netto is a highly deserving candidate for the Best Researcher Award in recognition of his academic excellence, impactful research in biotechnology and toxicology, and dedication to addressing critical issues in environmental and public health. He holds a Bachelor’s degree from Universidade Potiguar, a postgraduate specialization in Clinical and Toxicological Analysis (DACT/UFRN), and is currently pursuing his Ph.D. in Biotechnology through the esteemed RENORBIO program at the Federal University of Rio Grande do Norte (UFRN). His doctoral research focuses on biotechnological solutions for water decontamination and health applications — a field with immense societal relevance.

🎓 Education

  1. Ph.D. Candidate in Biotechnology (Biotecnologia em Saúde)
    🏛️ Universidade Federal do Rio Grande do Norte (UFRN) – RENORBIO
    📍 Natal, Brazil | ⏳ 2020 – Present
    🔬 Focus: Biotechnology applied to health, nanotechnology, and biosystems

  2. Graduate Specialization in Clinical and Toxicological Analysis
    🏛️ UFRN – DACT/CCS
    📍 Natal, Brazil | ⏳ 2019 – 2021
    🧪 Clinical biochemistry, toxicological testing, and environmental diagnostics

  3. Bachelor’s Degree in Biomedicine
    🏛️ Universidade Potiguar (UnP)
    📍 Natal, Brazil | ⏳ 2014 – 2018
    🧬 Emphasis on biomedical sciences and lab research

💼 Work Experience & Research Contributions

  • Doctoral Researcher – UFRN / RENORBIO
    🔬 Investigating biotechnological solutions for health applications, including nanoemulsions and natural compounds like Copaiba oil.
    🧪 Focus on drug delivery systems and water decontamination.

  • Co-author of Peer-Reviewed Scientific Articles & Book Chapters
    ✍️ Published works in International Journal of Molecular Sciences, and co-authored chapters in books on nanotechnology and environmental sciences.

🏆 Key Publications & Scientific Contributions

  1. “Bioavailability for the Improved Therapeutic Profile of trans-Dehydrocrotonin…”
    📰 International Journal of Molecular Sciences, 2025
    📌 Involves self-nanoemulsifying drug delivery systems and antioxidant testing
    🔗 DOI: 10.3390/ijms26104469

  2. “Copaiba oil as a natural product challenge…”
    📘 Applications and Industrialisation of Nanotechnology, 2022
    🌱 Explores Copaiba oil in pharmacology and biotechnology

  3. “Medições de índices de contaminantes em água…”
    📕 Águas potáveis: padrões de qualidade…, 2022
    🚰 Studies on water contamination and purification techniques
    🔗 DOI: 10.51859/amplla.app2385-7

🏅 Achievements & Honors

  • 🧪 Recognized Contributor to Brazilian biotechnology research in health and environmental applications

  • 📚 Author in interdisciplinary fields merging natural product chemistry, pharmacology, and nanotech

  • 💧 Environmental Advocate through water purification research in Brazilian urban areas

Publication Top Notes

Bioavailability for the Improved Therapeutic Profile of <i>trans</i>-Dehydrocrotonin Incorporated into a Copaiba Oil Self-Nanoemulsifying Drug Delivery System: Formulation, Physicochemical Characterizations, and Antioxidant In Vitro Effect

Copaiba oil as a natural product challenge in the chemistry, pharmacological and biotecnological fields

PROBLEMÁTICA DA OCORRÊNCIA DE NITRATO NAS ÁGUAS DO AQUÍFERO DUNAS-BARREIRAS DA CIDADE DE NATAL/RN

TECNOLOGIAS DESENVOLVIDAS PARA REMOÇÃO DE NITRATO EM ÁGUAS POTÁVEIS

ÁGUAS POTÁVEIS: PADRÕES DE QUALIDADE E SUSTENTABILIDADE